Archive: January 2025

Management of Oligoprogressive and Oligopersistent Disease in Advanced NSCLC

Abstract: The oligometastatic disease state is defined as an intermediate state between localized cancer and widespread systemic metastases. Oligoprogression is defined as a subgroup in which […]

Personalized Approaches to Breast Radiotherapy: Strategies for Treatment Refinement

Abstract: Radiotherapy (RT) is a crucial component of the adjuvant treatment of breast cancer that often follows breast conservation or mastectomy to further reduce the risk […]

Letter From the Editor: Lumpers and Splitters

I was having a dinner conversation with some of my oncology colleagues when the topic of lumpers vs splitters came up. We were talking about none other […]

Novel Approaches to Optimization of Drug Dosages

H&O  What does it mean to optimize drug dosage? CM  Drug dosage encompasses the volume of the drug taken at a particular time, how often the […]

Chimeric Antigen Receptor T-Cell Therapy for T-Cell Acute Lymphocytic Leukemia

H&O  What are the limitations of current treatments for T-cell acute lymphocytic leukemia (ALL)? IA  Although with modern ALL regimens the outcomes for patients with newly […]

The Role of CTLA-4 Inhibition in Immunotherapy for MSI-H/dMMR Metastatic Colorectal Cancer

H&O  When is immunotherapy used in microsatellite instability–high/mismatch repair–deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)? CW  Immunotherapy is used for patients with mCRC whose tumors test positive […]

Is MRD Testing Ready for General Use in Chronic Lymphocytic Leukemia?

H&O  What are the potential uses of measurable residual disease (MRD) testing in patients with chronic lymphocytic leukemia (CLL)? CO  The most important use of MRD […]

New Cell Surface Targets in Prostate Cancer

H&O  Could you provide a brief overview of cell surface targets in cancer treatment? AJA  Cell surface targets are very accessible and engageable, and therapies based […]

Back to Archive